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SUMMARY
PD-L1 on the surface of tumor cells binds its receptor PD-1 on effector T cells, thereby 
suppressing their activity. Antibody blockade of PD-L1 can activate an anti-tumor immune 
response leading to durable remissions in a subset of cancer patients. Here, we describe an 
alternative mechanism of PD-L1 activity involving its secretion in tumor-derived exosomes. 
Removal of exosomal PD-L1 inhibits tumor growth, even in models resistant to anti-PD-L1 
antibodies. Exosomal PD-L1 from the tumor suppresses T cell activation in the draining lymph 
node. Systemically introduced exosomal PD-L1 rescues growth of tumors unable to secrete their 
own. Exposure to exosomal PD-L1-deficient tumor cells suppresses growth of wild-type tumor 
cells injected at a distant site, simultaneously or months later. Anti-PD-L1 antibodies work 
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additively, not redundantly, with exosomal PD-L1 blockade to suppress tumor growth. Together, 
these findings show that exosomal PD-L1 represents an unexplored therapeutic target, which could 
overcome resistance to current antibody approaches.
Graphical Abstract
In Brief
Exosomal PD-L1 systemically acts to suppress the anti-tumor immune response, and its genetic 
blockage promotes T cell activity in the draining lymph node to induce systemic anti-tumor 
immunity and memory.
INTRODUCTION
Immunotherapy has revolutionized cancer therapy (Chen and Mellman, 2017). Immune 
checkpoint protein inhibitors, such antibodies against PD-L1 (aka CD274) and PD-1 (aka 
PDCD1), have shown effectiveness against a large number of cancer types, including 
melanoma, non-small-cell lung cancer, and renal cancer. This response includes durable 
remissions many patients who had previously failed multiple other therapeutic strategies. 
However, even in these cancers, only 10%–30% patients respond to anti-PD-L1/PD-1 
therapy (Page et al., 2014). In other cancers, such as prostate cancer, responses are rare 
(Goswami et al., 2016; Sharma et al., 2017). The basis differential therapeutic success 
between patients and between cancers remains largely unknown.
PD-L1 is a membrane bound ligand found on the cell surface of many cell types that is 
upregulated in the setting of inflammation and/or a number of oncogenic lesions (Topalian et 
al., 2015). It binds the PD-1 receptor on immune T cells, leading to Sh2p-driven 
dephosphorylation of the T cell receptor and its co-receptor CD28, thereby suppressing 
antigen-driven activation of T cells (Hui et al., 2017; Yokosuka et al., 2012). This 
mechanism normally keeps inflammatory responses in check, and Pd-l1 knockout mice 
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develop autoimmune-like diseases (Francisco et al., 2010). However, tumor cells can co-opt 
this mechanism to evade immune destruction. Therapeutic antibodies to PD-L1 and PD-1 
block this interaction, which can then reactivate the anti-tumor immune response (Chen and 
Mellman, 2017).
It is generally thought that PD-L1 functions within the tumor bed, where cell-surface PD-L1 
is directly interacting with PD-1 on the surface of tumor-infiltrating lymphocytes (TILs) 
(Mellman et al., 2011). However, PD-L1 also can be found on surface of extracellular 
vesicles (EVs). Furthermore, EV PD-L1 levels have been associated with tumor progression 
(Chen et al., 2018; Ricklefs et al., 2018; Theodoraki et al., 2018; Yang et al., 2018). Whether 
extracellular PD-L1 can promote tumor progression by inducing a local and/or systemic 
immunosuppression is unknown.
EVs are heterogeneous (Tkach et al., 2018). A particular form of EVs is exosomes, which 
derive from the endocytic pathway (van Niel et al., 2018). As endosomes mature, vesicles 
bud inward and are released in the lumen forming intravesicular bodies within the late 
endosomes. These late endosomes are also called multivesicular bodies (MVB). MVBs can 
either fuse with lysosomes for degradation and recycling of contents or fuse with the plasma 
membrane releasing the intravesicular bodies extra-cellularly, which are then called 
exosomes. Exosomes can be differentiated from other EVs based on their size, morphology, 
density, marker expression, and dependency for specific enzymes for their biogenesis. Key 
enzymes in their biogenesis include NSMASE2 (aka SMPD3), which promotes budding of 
intravesicular vesicles, and RAB27A, which is involved in the fusion of the MVB to the 
plasma membrane (Kosaka et al., 2010; Ostrowski et al., 2010). Genetic manipulation of 
these enzymes provides an opportunity to dissect the role of exosomes in vivo.
While evaluating mechanisms regulating levels of PD-L1 in different tumors, we discovered 
that cancer cells can secrete a vast majority of their PD-L1 on exosomes rather than present 
PD-L1 on their cell surface. Using genetic knockouts for Rab27a and nSMase2 and 
exogenously introduced exosomes, we show that exosomal PD-L1 from tumor cells promote 
tumor growth in an immune-dependent fashion. Exosomal PD-L1 suppresses T cell function 
in vitro and in vivo at the site of the draining lymph node. Exosomal PD-L1 appears to be 
resistant to anti-PD-L1 as a prostate cancer syngeneic model that is unresponsive to such 
therapy, is dependent on both PD-L1 and exosomes for their growth. Remarkably, even the 
transient presence of cancer cells deficient in exosomal PD-L1 results in long-term, systemic 
immunity against the cancer. A role for exosomal PD-L1 is also seen in a syngeneic 
colorectal model. In this model, anti-PD-L1 acts additively, not redundantly, with the 
suppression of PD-L1 secretion. These findings have significant implications for 
immunotherapeutic approaches to cancer therapy.
RESULTS
Differential Secretion of PD-L1 between CancerCell Lines
It has been reported that surface PD-L1 levels are low in prostate cancer cell lines and 
primary prostate tumor tissue, potentially explaining the general lack of therapeutic response 
to anti-PDL1 blockade (Martin et al., 2015; Zang et al., 2007). We sought to determine 
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whether a transcriptional, post-transcriptional, translational, or post-translational mechanism 
underlies the reduced levels by comparing prostate cancer cell lines (PC3, DU145, LNCaP) 
to a melanoma cell line (SK-MEL-28). Measurements of mRNA and protein levels showed 
discordance between mRNA and protein levels across the different cancer cell lines. qRT-
PCR showed a 15-fold increase of Pd-l1 mRNA levels in PC3 and DU145 relative to SK-
MEL-28; LNCaP showed a near absence of transcripts (Figure 1A). In contrast to mRNA 
levels, western analysis showed similar cellular PD-L1 protein levels in PC3 and DU145 
cells as SK-MEL-28 (Figure 1B); protein was undetectable in LNCaP cells. We asked 
whether the discordance in mRNA and protein levels between PC3 and SK-MEL-28 could 
be explained by differences in protein translation. Translation rates were determined by 
polysome profiling, a method by which transcripts bound by many ribosomes reflective of a 
high translation rate are separated from transcripts bound by one or a few ribosomes 
reflective of a low translation rate (Chassé et al., 2017). The two populations were separated 
on a sucrose gradient, and then the bound mRNA was measured by qRT-PCR (Figure S1A). 
This analysis showed an equal distribution of the Pd-l1 RNA across the fractions in PC3 and 
SK-MEL-28 (Figure S1B). Thus, differences in translation rates cannot explain the 
discordance between mRNA and protein levels between the lines.
Next, we evaluated potential differences in protein degradation. The two main pathways for 
protein degradation are the lysosome and the proteasome (Ciechanover, 2005). The small 
molecule Bafilomycin A1 (BafA1) inhibits lysosomal activity by blocking the V-ATPase 
hydrogen pump and thus acidification of the lysosome (Mauvezin and Neufeld, 2015). An 
increase in the protein LC3B, a known target of the lysosome, confirmed effectiveness of the 
small molecule on PC3 and SK-MEL-28 cells. However, levels of PD-L1 in both lines were 
unaltered, implying little turnover of PD-L1 by the lyso-some in these cells (Figures S1C 
and S1D). The small molecule MG132 suppresses proteasome activity by blocking the 26S 
proteasome complex and, consequentially, proteolysis (Lee and Goldberg, 1998). The 
proteasome recognizes ubiquitin side chains on its targets (Lee and Goldberg, 1998). An 
increase in the presence of ubiquitinated proteins confirmed the effectiveness of MG132 on 
the two cells lines. Again though, PD-L1 protein levels were minimally affected, and, if 
anything, the difference of the two lines was opposite from expected as PD-L1 levels were 
slightly up in SK-MEL-28, but not in PC3, cells (Figures S2E and S2F). These results show 
that differences in protein stability do not explain the discordance in mRNA and protein 
levels.
Next, we considered the possibility that PD-L1 may be differentially secreted from cells in 
the form of membrane vesicles. Extra-cellular vesicles can be enriched using sequential 
centrifugation transferring supernatant through increasing gravitational forces to remove 
cellular debris and apoptotic bodies, before finally pelleting at 100,000 gravitational forces 
(100k g) (Xu et al., 2016). Western analysis showed 2- to 3-fold more PD-L1 in the 100k g 
fraction of PC3 cells relative to SK-MEL-28 cells (Figure 1C). This difference could have 
been due to more PD-L1 being loaded per vesicle or release of more vesicles. A nanoparticle 
tracking instrument can track the size and number of vesicles by using light diffraction off 
particles moving under Brownian motion (Carr and Warren, 2012). Analysis of conditioned 
media from the two cell types showed a slightly elevated total vesicle count in SK-MEL-28 
(Figure 1D). Thus, even though PC3 and SKMEL-28 cells had similar levels of cellular PD-
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L1 protein, PC3 cells packaged greater amounts of PD-L1 into extracellular vesicles. This 
difference appears to underlie the discordance between mRNA and protein levels between 
the two cell lines.
In vivo, tumor cells can mediate adaptive resistance by upregulating PD-L1 in response to 
interferon-gamma (IFNγ) released by the cytotoxic T lymphocytes within the tumor bed 
(Garcia-Diaz et al., 2017). Therefore, we asked whether, in addition to up-regulating cellular 
PD-L1, IFNγ may increase the secretion of PD-L1. Treatment of cancer cells with IFNγ led 
to an increase in PD-L1 in both the cellular and 100k g fractions (Figure S2A). The increase 
was proportionally similar between the two fractions, suggesting no direct impact of IFNγ 
on PD-L1 secretion (Figure S2B). In addition, IFNγ did not increase the number of vesicles 
secreted (Figure S2C). Thus, similar to the cell-surface membrane PD-L1, extracellular 
vesicular PD-L1 increases in response to IFNγ.
PD-L1 Is Specifically Secreted within Exosomes
Extracellular vesicles come in multiple forms differing in size, density, protein markers, and 
biogenesis (Xu et al., 2016). Given that PD-L1 is endocytosed from the surface of cells 
(Burr et al., 2017; Mezzadra et al., 2017), we hypothesized that PD-L1 is being specifically 
secreted in the form of exosomes. Exosomes can be enriched relative to other vesicles based 
on their density by spinning the crude 100k g pellet on a sucrose gradient (Shurtleff et al., 
2016). The exosomal marker CD63 traveled in the 20%–40% sucrose fractions (Figure 1E). 
PDL1 and the additional exosomal marker HRS colocalized with CD63 (Figure 1F). These 
data support that PD-L1 is packaged in exosomes.
Next, to determine if PD-L1 is specifically found in exosomes, we took a genetic approach 
to remove exosomes. We focused on the Rab27a and nSMase2 genes using CRISPR/Cas9-
mediated mutagenesis to knock them out in PC3 cells (Figures S3A–S3C). Deletion of these 
two genes did not affect the proliferation of PC3 cells (Figures S3D and S3E). To follow 
exosomes, we ectopically expressed CD63-GFP in the three genetic backgrounds. 
Measurement of the conditioned media showed an almost complete absence of CD63-GFP+ 
particles arising from the two mutant lines versus wild-type (WT) (Figure 2A). To further 
evaluate the effect of the Rab27a and nSMase2 deletion on exosomes, we performed 
electron microscopy on sucrose gradient concentrated particles. The resultant images 
showed very few exo-some-like particles in the Rab27a and nSMase2 null samples, with a 
greater loss in the Rab27a null cells (Figures 2B–2dD). Consistent with these images, 
western analysis showed an absence of endogenous CD63 in the 100k g preps from Rab27a 
null cells and a small amount remaining in the nSMase2 null cells (Figure 2E). In contrast to 
CD63 levels, nSMase2 showed a complete absence, while Rab27a null cells showed a 
dramatic reduction in PD-L1 in the 100k g fraction (Figure 2E). This difference appears to 
be due to an additional role for NSMASE2 on Pd-l1 transcription (Figures S3F and S3G). 
Together, these data show critical roles for both Rab27a and nSMase2 in exosome 
biogenesis and PD-L1 secretion.
Given that PD-L1 is a trans-membrane protein, exosomal PDL1 must arise from the limiting 
membrane of the late endosome. The limiting membrane of the late endosome initially arises 
from the endocytosis of the plasma membrane. However, material provided directly from the 
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ER and Golgi as well as cytoplasm is added as the resultant endosome matures (van Niel et 
al., 2018). Flow cytometry and immunofluorescence showed the presence of PD-L1 on both 
the surface and within vesicle-like structures inside PC3 cells (Figures S4A and S4B). Using 
standard cell fractionation techniques, PD-L1 and CD63 co-localized in the sucrose light, or 
endolysosomal fraction (Shurtleff et al., 2016) (Figure S4C). To determine whether 
exosomal PD-L1 directly arises from the ER or early Golgi, we took advantage of the fact 
that PD-L1 is glycosylated (Li et al., 2016). This glycosylation was easily removed with the 
amidase PNGaseF, consistent with it being a N-linked oligosaccharide chain (Figure S4D). 
In contrast, the majority of cellular and all the exosomal PD-L1 was resistant to EndoH 
cleavage, consistent with maturation of the oligosaccharide chain in the distal Golgi 
(Stanley, 2011). Therefore, exosomal PD-L1 does not appear to come directly from the ER 
or early Golgi. To measure the plasma membrane as a source, we performed a cell-surface 
biotinylation assay (Figure S4E). Biotin-labeled PD-L1 was found in the cells and exosomes 
of treated cells, showing that exosomal PD-L1 originates from the surface of the PC3 cells.
Exosomal PD-L1 Suppresses T Cell Activation In Vitro
Next, we asked whether exosomal PD-L1 could function similarly to cell-surface PD-L1 in 
the suppression of T cell activation. PD-L1 function can be measured in vitro in the setting 
of Raji B cell presentation of antigen to Jurkat T cells (Hui et al., 2017). Normally, this 
presentation would activate T cells, which can be measured by secretion of interleukin-2 
(IL-2). However, if PD-L1 is exogenously expressed in the Raji B cells and PD-1 is 
exogenously expressed in the Jurkat T cells, T cell activation is suppressed (Hui et al., 
2017). In this setting, we asked whether exosomal PD-L1 from PC3 cells could replace 
exogenous expression of PD-L1 on the Raji B cells (Figure 2G). As expected, in the absence 
of exogenous expression of PD-L1 in Raji B cells, IL-2 secretion was high (Figure 2H, 
compare first two bars). However, the introduction of the PC3 100k g extracellular fraction 
re-repressed IL-2 secretion showing that PC3 vesicles can replace Raji cell PD-L1 
expression (Figure 2H, third bar). To determine whether exosomal PD-L1 was responsible 
for this effect, we used CRISPR/Cas9 editing to delete the Pd-l1 gene in the PC3 cells 
(Figure S4F). Deletion of the Pd-l1 gene did not affect the proliferation of the PC3 cells or 
alter the number of vesicles released (Figures S4G and S4H). However, introduction of the 
Pd-l1 null PC3 100k g extracellular fraction failed to repress IL2 secretion (Figure 2H, 
fourth bar). These data show that exosomal PD-L1 does function to suppress T cell 
activation in vitro.
Exosomal PD-L1 Promotes Tumor Progression
Given its ability to suppress T cell activation in vitro, we wanted to know whether exosomal 
PD-L1 can function in vivo to promote tumor progression. To do so, we turned to a 
syngeneic model of prostate cancer, the TRAMP-C2 model (Foster et al., 1997). This 
preclinical model, like human prostate cancer, is resistant to anti-PD-L1 blockade (Yu et al., 
2012). CRISPR/Cas9-mediated deletion of Rab27a (Figure S5A) and Pd-l1 (Figure S5B) 
resulted in a loss of PD-L1 in the EV fraction (Figure 3A). Loss of Rab27a did not influence 
cell-surface PD-L1 levels, nor did loss of Pd-l1 influence exosome production (Figures S5C 
and S5D). Like with the PC3 cells, deletion of Rab27a or Pd-l1 did not affect the 
proliferation of the cells (Figures 3B and 3C). The WT, Rab27a null, and Pd-l1 null 
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TRAMP-C2 cells were injected into the flanks of C57BL6/J syngeneic mice and were 
followed for over 4 months. All mice injected with the WT TRAMP-C2 cells had visible 
tumors by around 35 days and had to be euthanized between 40 and 71 days (Figures 3D and 
3E). In contrast, all mice injected with Rab27a null or Pd-l1 null TRAMP-C2 cells showed 
no tumor growth during the same time period (Figure 3D). Similarly, the mice injected with 
Rab27a and Pd-l1 null TRAMP-C2 cells showed a dramatically extended lifespan relative to 
their WT counterparts (Figure 3E). Indeed, a majority of the mice remained alive after 90 
days, at which point they were used for the memory experiments described below.
To further confirm that the loss of Rab27a was blocking tumor growth through its role in 
exosome biogenesis, we repeated the experiments using nSMase2 null cells. nSMase2 was 
deleted again using CRISPR/Cas9-mediated mutagenesis (Figure S5E). Similar to PC3, 
nSMase2 null TRAMP-C2 cells showed a decrease in both cellular and extracellular levels 
of PD-L1 (Figures S5F–S5H). These cells were injected in syngeneic mice and compared to 
their WT counterparts. Similar to Rab27a null TRAMP-C2 cells, the nSMase2 null 
TRAMP-C2 cells failed to form palpable tumors during the time period when mice receiving 
WT cells had to be euthanized (Figure 3D). Again, a majority of the mice (8 of 10) were still 
alive after 90 days (Figure S3E). Together, these data show that blocking exosome 
biogenesis or removing PD-L1 result in a very similar tumor growth suppression phenotype.
It remained plausible that the exosome biogenesis factors were acting cell autonomously to 
suppress tumor growth, rather than non-autonomously via exosomal PD-L1 to suppress 
tumor growth via the anti-tumor immune response. To differentiate these alternative 
possibilities, we next asked whether the effect of Rab27a and/or nSMase2 loss was 
dependent on an active immune system. WT, Rab27a, nSMase2, and Pd-l1 null TRAMP-C2 
cells were injected into NOD-scid IL2rγnull (NSG)-immunodeficient mice. In striking 
contrast to the results seen in immunocompetent mice, the four lines led to end-stage tumors 
at a similar rate in the immunodeficient background (Figure 3E). Therefore, RAB27A and 
NSMASE2, like PD-L1, promote tumor growth through the suppression of the immune 
system.
Exosomal PD-L1 Suppresses T Cell Activity in the Draining Lymph Node
Next, we asked whether loss of exosomes and PD-L1 have a similar effect on the immune 
response to the tumor. To address this question, we measured the response in the lymphoid 
tissues following the injection of WT, Rab27a null, and Pd-l1 null TRAMP-C2 cells (Figure 
4A). At 14 days, the spleens of mice injected with either mutant cell line were significantly 
larger than those injected with WT cells (Figure 4B). Immunophenotyping of the spleen 
showed equal percentages of CD8, CD4, and regulatory T cells across the three genotypes 
(Figure S6). These data are consistent with an enhanced generalized systemic immune 
response in the absence of exosomes or PD-L1. In contrast, immunophenotyping of the 
draining lymph nodes showed striking differences between the WT and mutant animals. 
CD8 positive cells made up a much greater fraction of the T cells following injection of the 
two mutant tumor cell lines relative to the WT line (Figure 4C). The fraction of CD4 was 
relatively down in the mutants, whereas FoxP3+ T regulatory cells composed a constant 
fraction of the T cells (Figures 4D and 4E). Given the relative increase in CD8 cells in the 
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absence of exosomes or PD-L1, we evaluated markers of T cell exhaustion and activation 
within the CD8 and CD4 T cell populations. The fraction of CD8 and CD4 cells that were 
PD-1 high were trending down in mice receiving the mutant cells (Figures 4F and 4G). 
Much more significant was a decrease in the percentage of cells expressing the exhaustion 
marker Tim3 and increase in the percentage of cells expressing the activation marker 
Granzyme B (Figures 4H–4K). Furthermore, the fraction of cells positive for the 
proliferation marker Ki67 was significantly up among the CD8 T cells and trending up 
among the CD4 T cells (Figure 4L and 4M). These data are consistent with tumor-derived 
exosomal PD-L1 traveling to the draining lymph node and suppressing T cell activation.
We hypothesized that if exosomes are acting through PD-L1 to suppress the T cell activation 
in the lymph node, then in the absence of exosomal PD-L1, immune-competent mice will 
not only suppress immediate growth of the mutant tumor cells but will also develop memory 
toward the tumor cells. To test this hypothesis, mice injected with either Rab27a or Pd-l1 
null TRAMP-C2 cells on one flank were rechallenged 90 days later with WT TRAMP-C2 
cells on the other flank (Figure 4N). Age matched mice that had not been previously injected 
with any tumor cells were used as control. Remarkably, WT TRAMP-C2 tumors failed to 
grow in any of the mice previously injected with either mutant cell line, but showed normal 
growth in the age matched controls (Figure 4O). Thus, exposure to tumor cells lacking 
exosomes or PD-L1 results in a robust memory response even against cells that secrete 
exosomal PD-L1. We interpret this to mean that once the T cells have been exposed to tumor 
antigens in the absence of exosomal PD-L1, they become resistant to the suppressive effects 
of exosomal PD-L1.
Exosomal PD-L1 Promotes Growth across Different Tumor Types
Next, we asked whether the effect of exosomal PD-L1 on tumor progression is unique to the 
TRAMP-C2 model. To address this question, we evaluated a colorectal cancer model, 
MC38. Unlike the TRAMP-C2 model, this model shows a partial response to anti-PD-L1 
and therapy (Deng et al., 2014). Western analysis showed that MC38 cells, like TRAMP-C2 
cells, secrete PD-L1 (Figure 5A). They also express low levels on the cell surface (Figure 
5B). Using identical guide RNAs as in the TRAMP-C2 model, Pd-l1 and Rab27a were 
knocked out in MC38 cells via CRISPR/Cas9-mediated mutagenesis (Figures 5B and S7A). 
The Rab27a knockout cells showed a loss of PD-L1 in the secreted fraction, confirming the 
packaging of PD-L1 in exosomes (Figure 5A). Also, similar to TRAMP-C2 cells, the 
Rab27a and Pd-l1 knockout MC38 cells showed no change in proliferation (Figures 5C and 
5D). These cells were injected in syngeneic WT mice (Figures 5E and 5F). WT MC38 
tumors grew rapidly, and mice had to be euthanized starting at 9 days. Loss of either Rab27a 
or Pd-l1 slowed tumor growth and extended lifespan. However, unlike the TRAMP-C2 
model, Pd-l1 loss had a greater effect than Rab27a loss (Figure 5F). Therefore, exosomal 
PD-L1 appears to play an important, but partial role, in this model.
The difference in the effect of Pd-l1 versus Rab27a loss allowed for an epistasis analysis to 
address the question of whether exosomes are acting specifically through PD-L1 to influence 
tumor growth. If exosomes have a PD-L1 independent role, their removal should further 
reduce tumor growth and extend lifespan in the Pd-l1 null background. Therefore, we made 
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Rab27a; Pd-l1 double knockout MC38 cells (Figure S7). These cells grew at a rate similar to 
that of the Pd-l1 single mutant cells (Figures 5E and 5F). Thus, we conclude that exosomes 
are functioning predominantly, if not entirely, through their presentation of PD-L1.
The difference in the effect of Pd-l1 versus Rab27a loss on tumor growth also implied that 
there is an exosome independent pool of PD-L1 that is also functioning to suppress the 
immune response in this model. We hypothesized that unlike exosomal PD-L1, this pool 
may be sensitive to anti-PD-L1 antibody. This pool could explain why unlike the TRAMP-
C2 model, the MC38 model is partially responsive to anti-PD-L1 antibodies (Deng et al., 
2014). To test this hypothesis, we evaluated the effect on survival of anti-PD-L1 alone and in 
combination with exosome depletion. Similar to the loss of Rab27a, the treatment of the 
mice with anti-PD-L1 antibody extended survival, but not to the same degree as loss of Pd-l1 
(Figure 5G). Remarkably, the combination of Rab27a deletion and treatment with anti-PD-
L1 antibodies lead to similar survival curve as the Pd-l1 deletion. This finding strongly 
supports the conclusion that while exosomal PD-L1 is resistant to anti-PD-L1, there is 
another pool in this model, likely cell-surface PD-L1, which is both a significant suppressor 
of the anti-tumor immune response and sensitive to the antibodies.
Exosomal PD-L1-Deficient Tumor Cells Can Suppress WT Tumor Growth at a Distance Site
Exosomes can enter the blood and lymphatic systems and travel throughout the body, 
potentially influencing tumor growth at distant sites (Ruivo et al., 2017). Similarly, immune 
cells educated at one tumor site can travel throughout the body potentially influencing 
growth of tumors at distant sites (Chen and Mellman, 2013). Therefore, we next asked 
whether the simultaneous injection of WT and mutant cells at different sites would affect 
growth of either tumor. In particular, could exosomal PD-L1 released from WT tumor cells 
promote growth of mutant cells at a distant site, and/or could the T cells activated by the 
mutant cells suppress growth of WT cells at a distant site? To address this question, WT 
TRAMP-C2 cells were injected in one flank of each mouse simultaneously with Pd-l1, 
Rab27a, or nSMase2 null TRAMP-C2 cells on the other flank (Figure 6A). Tumor growth 
on each flank was then followed over time. Remarkably, growth of the WT tumor in these 
double injections was dramatically reduced relative to mice where WT cells alone were 
injected (Figure 6B). The effects of Pd-l1, Rab27a, or nSMase2 null cells on the distant WT 
tumor were similar. In contrast, the WT cells did not have any effect on the growth of 
Rab27a or nSMase2 null cells (Figure 6C). However, the WT cells did promote the growth 
of Pd-l1 null cells. This effect was small as tumor growth was much slower than the WT 
counterparts (Figure 6C, compare y axis to 6B). The reason for the difference between the 
Pd-l1 null cells and the exosome-deficient cells is unclear and requires further study. 
Overall, the double-injected mice had a greatly extended survival relative to those that 
received WT TRAMP-C2 cells alone (Figure 6D). These findings strongly supported the 
notion that immune cells activated in the draining lymph node of the mutant side were able 
to travel and attack the WT tumor cells on the opposite flank. Indeed, histological analysis 
of the WT tumors showed a dramatic increase in the number of infiltrating lymphocytes 
when co-injected with the mutant cells on the opposite flank (Figures 6E and S7E). 
Together, these data show communication between the tumors, with the effect of the mutant 
tumor being dominant over that of the WT tumor.
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Exogenously Introduced Exosomal PD-L1 Can Rescue Immune Suppression and Tumor 
Growth
Next, we asked whether exogenously introduced exosomal PDL1 could suppress the anti-
tumor immune response and promote tumor growth. To address the effect on the immune 
response, we transplanted Rab27a null TRAMP-C2 cells in the flank of syngeneic mice 
followed by tail vein injections of in vitro collected exosomes from either their WT or Pd-l1 
null counterparts (Figure 7A). Exosomes from the WT, but not Pd-l1 null, cells were able to 
induce a systemic immunosuppression as evidenced by nearly a 50% reduction in spleen 
size (Figure 7B). Furthermore, the WT exosomes were able to suppress the immune 
response in the draining lymph node of the Rab27a-deficient cells. Compared to the Pd-l1-
deficient exosomes, the WT exosomes led to a reduced CD8/CD4 ratio, while having little 
effect on the T-reg cells (Figures 7C–7E). More importantly, they led to an increase in the 
fraction of cells expressing high levels of the exhaustion markers PD-1 and TIM3 and low 
levels of the activation marker Gramzyme B (Figures 7F–7K). These findings paralleled the 
findings seen in mice transplanted with WT versus Rab27a null cells (cf. Figures 4 and 7). 
To address the effect on the tumor growth, we transitioned to the MC38 model, given its 
more rapid growth characteristics. As with the TRAMP-C2 model, Rab27a-deficient MC38 
cells were injected in the flank of syngeneic mice followed by exosome injection in the tail 
vein of the same mice. Consistent with the immune suppression seen in the TRAMP-C2 
model, injection of exosomes collected from WT, but not Pd-l1-deficient MC38, cells 
promoted tumor growth and reduced survival (Figures 7L and 7M). These results confirm 
that exosomes are functioning through PD-L1 to suppress the anti-tumor immune response 
and thus promote tumor growth.
DISCUSSION
All together, these data uncover a key role for exosomal PD-L1 in enabling cancer cells to 
evade anti-tumor immunity. Indeed, in the presence of exosomal PD-L1, T cells in the 
tumor’s draining lymph node express markers of exhaustion and the spleens are smaller. 
Genetically blocking exosome biogenesis or deleting Pd-l1 reverses the phenotype by 
strongly promoting T cells activation, proliferation, and killing potential. This effect is 
reversed again with the introduction of exogenous exosomal PD-L1. Therefore, tumor 
exosomes have the ability to travel to the draining lymph node, where they present PD-L1 
inhibiting T cell activation. Remarkably, blocking the release of exosomal PD-L1 not only 
suppresses growth of the local tumor cells but also blocks WT tumor cells injected at a 
distant site either simultaneously or months later. Therefore, enabling T cell activation at the 
local lymph node leads to a durable systemic immune response that is no longer affected by 
the secretion of exosomal PD-L1. The end result is extended survival of the afflicted mice.
A role for EVs, including exosomes, in tumor progression has been proposed in a number of 
settings (Ruivo et al., 2017). EVs can carry tumor antigens. When taken up by dendritic 
cells, these antigens can be presented, thereby inducing an immune response (Wolfers et al., 
2001). As such, EVs were originally thought to have an anti-tumor effect. However, more 
recent studies have suggested a number of immunosuppressive effects. For example, EVs 
can inhibit dendritic cell maturation, natural killer (NK) cell function, and directly kill CD8 
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T cells (Abusamra et al., 2005; Liu et al., 2006; Yu et al., 2007). EVs also have been shown 
to promote directional migration of tumor cells (Sung et al., 2015), home tumor cells to 
lymph nodes (Hood et al., 2011), induce neovascularization and leakiness of tumor vessels 
(Peinado et al., 2012; Skog et al., 2008; Zhou et al., 2014), and, even, establish pre-
metastatic niches (Fong et al., 2015; Hoshino et al., 2015). The mechanisms behind these 
various functions remain largely speculative.
Here, we present extensive evidence that EVs, specifically exosomes, can function to 
promote tumor progression by presenting PD-L1. In vitro, exosomes suppressed T cells in a 
PD-L1-dependent fashion. In vivo, the removal of tumor exosomes from TRAMP-C2 cells 
using two independent genetic mutations recapitulated the effects of deleting Pd-l1. These 
recapitulated effects included suppression of tumor growth, increased cellularity of the 
spleen, and the activation of a T cell response in lymph nodes with similar effects on the 
various activation, exhaustion, and proliferation markers. All these outcomes were reversed 
with the injection of in vitro collected exosomes carrying PD-L1. In the absence of PD-L1, 
the exogenously introduced exosomes had little effect. Therefore, at least in the TRAMP-C2 
model, presentation of PD-L1 appears to be the major mechanism by which exosomes 
promote cancer progression.
This role for exosomal PD-L1 is not limited to the TRAMP-C2 model. Removal of 
exosomes in the colorectal MC38 model also suppressed tumor growth and extended 
survival. Once again, the effect was dependent on PD-L1 as the removal of exosomes had no 
additional effect in the Pd-l1 null background. Interestingly though, unlike the TRAMP-C2 
model, the loss of exosomes alone did not have as much of an impact as Pd-l1 loss, 
suggesting a combined role of exosomal and cellular PD-L1 in the MC38 model. 
Remarkably, combining exosome loss with anti-PD-L1 treatment extended survival of these 
mice to a similar degree as removing PD-L1 altogether. These data show that in the MC38 
model, both exosomal and cellular PD-L1 play an important role in promoting tumor 
progression in the latter, but not in the former, being sensitive to anti-PD-L1 therapy. 
Understanding what regulates the relative surface versus exosomal presentation of PD-L1 
will be an important avenue of research going forward.
Several recent papers have identified exosomal PD-L1 in the blood of patients with a variety 
of cancers including head and neck cancer and melanoma (Chen et al., 2018; Theodoraki et 
al., 2018). In melanoma, it has been further shown that patients resistant anti-PD-1 therapy 
have elevated levels of exosomal PD-L1 in their blood prior to treatment (Chen et al., 2018). 
Therefore, our findings on the immunosuppressive and tumor-promoting roles of exosomal 
PD-L1 are likely to be relevant across many cancer types. However, the degree to which 
exosomal versus surface PD-L1 is driving immunosuppression will vary between patients 
and cancer types. Identifying patients who are more or less dependent on exosomal PD-L1 
will be critical going forward in deciding those who are more likely to respond to therapy. 
Measuring levels in the blood as shown in these recent studies is likely to be one such 
strategy.
Going forward, targeting both cell-surface and exosome presentation of PD-L1 should be 
considered in any therapeutic strategy. The TRAMP-C2 model is resistant to current anti-
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PDL1 antibody blockade (Yu et al., 2012). However, the deletion of Pd-l1 in the tumor cells 
had a striking effect. Similarly, although the MC38 model shows partial responsiveness to 
anti-PD-L1 therapy (Deng et al., 2014), deletion of the Pd-l1 gene has a greater effect 
(Figure 5). These data are all consistent with exosomal PD-L1 being resistant to current anti-
PD-L1 therapy. The reason exosomal PD-L1 is resistant is unclear. It is possible that how 
PD-L1 is presented on the exosome makes it less responsive to the current antibodies. 
Alternatively, exosomal PD-L1 may be produced at high enough levels that it can compete 
with the delivered antibody. It is also possible that exosomes can reach targets that are 
sequestered from the effects of the antibody. It will be important to tease apart the 
interactions of exosomal PD-L1 with current therapeutics.
Potentially the most promising therapeutic implication of our findings is that inhibition of 
exosome secretion at one tumor site can lead to a systemic and durable immune response 
against distant tumor sites or secondary tumor challenges. This observation is reminiscent of 
the abscopal effect, originally seen in patients treated with irradiation (Ngwa et al., 2018). In 
particular, irradiation of the primary tumor can lead to secondary regression of metastases. It 
is thought that this phenomenon is driven by activation of anti-tumor immune response and 
preclinical studies combining irradiation with immunosuppression are underway (Ngwa et 
al., 2018). It will be interesting to determine whether localized anti-exosomal therapy 
combined with systemic anti-PD-L1 blockade could synergize to induce a systemic immune 
response against multiple tumor sites simultaneously.
Here, we used genetics to dissect the role of exosomal PD-L1 in tumor progression by 
deleting two important exosomal biogenesis genes: Rab27a and nSMNase2. The deletion of 
Rab27a led to loss of all exosomes as measured by markers (CD63, HRS), particle tracking, 
and electron microscopy. The deletion of nSMNase2 led to a loss of a majority, but not all, 
exosomes, as measured by the same assays. Therefore, both enzymes represent potential 
therapeutic targets. Small molecule inhibitors toward NSMNASE2 and RAB27A already 
exist, GW4869 and Nexinhib-20, respectively (Johnson et al., 2016; Luberto et al., 2002). 
However, these small molecules are unable to inhibit exosome release in multiple cancer cell 
lines, including PC3, or show an in vivo effect in the MC38 model (Phuyal et al., 2014) 
(Figures S7D–S7H), even though their respective knockouts had a profound effect (this 
paper). Therefore, there is a need for more effective small molecules toward these targets 
before any hope of developing them into drugs. Based on our findings, such drugs could 
have the potential to act alone or in combination with current immune-checkpoint therapies, 
reaching a large population of cancer patients.
In summary, we have discovered that exosomal PD-L1 is a major regulator of tumor 
progression through its ability to suppress T cell activation in draining lymph nodes and that 
its inhibition can lead to a long-lasting, systemic anti-tumor immunity.
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STAR★METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for all original resources and reagents presented in this 
manuscript should be directed and will be fulfilled by the Lead Contact, Robert Blelloch 
(robert.blelloch@UCSF.edu). MTAs may be required for some reagents per UCSF policy.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human tumor cell lines—PC3, DU145, LNCaP, SK-MEL-28 and 293T cells were 
obtained from ATCC, where they had been authenticated. PC3, DU145 and LNCaP are 
prostate cancer cell lines derived from male patients. SK-MEL-28 is a male melanoma cell 
line. PC3 were cultured in F-12K Medium (Kaighn’s Modification of Ham’s F-12 Medium) 
(GIBCO, ref 21127–022), 10% Fetal Bovine Serum (Corning, ref. 35-010-CV) and 
Penicillin/Streptomycin (Sigma, cat. P4333). DU145 were cultured in Eagle’s Minimum 
Essential Medium (EMEM) (Lonza, cat. 12–125Q), 2 mM L-glutamine (Sigma, cat. G7513), 
10% Fetal Bovine Serum (Corning, ref. 35-010-CV) and Penicillin/Streptomycin (Sigma, 
cat. P4333). LNCaP and SK-MEL-28 were cultured in RPMI-1640 Medium (Corning, 
15-040-CM), 10% Fetal Bovine Serum (Corning, ref. 35-010-CV), 2 mM L-glutamine 
(Sigma, cat. G7513), and Penicillin/Streptomycin (Sigma, cat. P4333). SK-MEL-28. Raji B 
cells and Jurkat T cells were cultured as previously reported (Hui et al., 2017). All cells were 
cultured at 37°C in a humidified atmosphere containing 5% CO2.
Mouse tumor cell lines—TRAMP-C2 cells were obtained from ATCC, where they had 
been authenticated, TRAMP-C2 cells were derived from a primary large T antigen 
expressing tumor that developed in a C57BL/6 male mouse (Foster et al., 1997). TRAMP-
C2 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (UCSF cell 
culture facility), 5% Nu-Serum IV (Fisher, cat. CB-55004, 500 ml, to be diluted to 5%), 5% 
Fetal Bovine Serum (Corning, ref. 35-010-CV), Bovine Insulin (Sigma, cat. I0516), DHEA 
(Sigma, D-063), and Penicillin/Streptomycin (Sigma, cat. P4333). MC38 cells were kindly 
provided by Jeffrey Schlom’s Lab and cultured in DME H-21 (Dulbecco’s Modified Eagle 
Medium) High Glucose (UCSF cell culture facility), 10% Fetal Bovine Serum (Corning, ref. 
35-010-CV), 1 mM sodium pyruvate (UCSF cell culture facility). MC38 cells are a colon 
cancer cell line derived from a female C57BL/6. All cells were cultured at 37°C in a 
humidified atmosphere containing 5% CO2.
Mice—C57BL/6J (stock # 000664) mice were purchased from “The Jackson Laboratory” 
and/or bred in the UCSF animal house. Immunodeficient mice NOD-
Prkdcem26Cd52Il2rgem26Cd22/NjuCrl (catalog # 24110022) were obtained from Charles River. 
Only male mice (approximately 8–10 weeks old unless otherwise specified in text) were 
used for all experiments. Mice were kept under the pre-approved guidelines of the 
Institutional Animal Care and Use Committee at UCSF. Mice were housed in pathogen free 
conditions. Mice dying for nonrelated cancer causes were excluded from the studies (i.e., 
fights or infections). Additional information (i.e., sample size, replicates) is described in the 
figure legends. Each experimental group was created with mice derived from different 
brood.
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METHOD DETAILS
Cell lines treatments—To inhibit lysosome function, cells were cultured with 250 nM 
BafA1 (Cell Signaling, cat. 54645S) for six hours. To inhibit proteasome function, cells 
were cultured in 10 uM of MG132 (SIGMA, cat, M7449) for six hours.
To investigate PD-L1 glycosylation, PC3 cell lysate were treated with PNGase F (Sigma-
Aldrich, cat. P7367). To investigate further glycosyl modification in the Golgi apparatus, 
PC3 cell lysate were treated with Endo H (NEB, cat. P0702S).
For IFN-γ treatments, 10ng/mL IFN-γ (PeproTech – human cells, cat. 300–02) (Abcam – 
mouse cells, cat. Ab9922) to media for 48 hours prior to exosome and cell collections.
For GW4869 treatments, 10μM GW4869 (Sigma-Aldrich, cat. D1692) to media for 48 hours 
prior media collections.
Exosome/Secreted Vesicle isolation—PC3 and SK-Mel-28 cells were plated at a 
density of 5 million per 15 cm plate (Corning 430599), cultured for 48 hours and media 
from six plates were pooled.
For TRAMP-C2 and MC38 secreted vesicle extractions, cells were plated at a density of 3 
million per 15 cm plate for 48 hours and media from 6 plates were pooled.
For vesicle enrichment, media was centrifuged at 300 g for 10 minutes at room temperature, 
followed by 2k g for 20 min at 4°C then 12k g for 40 minutes at 4°C. Supernatant was then 
centrifuged twice at 100k g, for 1 hour then 10 minutes at 4°C. For exosome purification, the 
100k g pellet was further spun on a sucrose gradient (20%–60% sucrose) for 16 hours at 4°C 
at 100k g. Fractions were collected and sucrose concentration measured using a 
refractometer.
It was noted that components of FBS lacked any reactivity to anti-human or anti-mouse PD-
L1 and thus in experiments where only proteins were measured, vesicles were collected 
directly from culture media described above. In experiments where vesicles or exosomes 
would be counted or visualized, FBS was replaced by Knock-out Serum Replacement (KSR, 
GIBCO 10828028) to exclude particles present in the FBS.
CRISPR–Cas9-mediated gene disruption—sgRNA oligonucleotides (ELIMBIO), 
were cloned into pSpCas9(BB)-2A-GFP (PX458, ADDGENE) according to the published 
protocol (Ran et al., 2013). For each gene disrupted, two different guides were 
simultaneously transfected. 1ug of each vector was transfected using FUGENE HD 
(Promega, cat. E2311). Pd-l1 null, Rab27a null and nSMase2 null clones were obtained by 
GFP+ single cell cloning, 48 hours post transfection. Knockout clones were identified either 
by western (RAB27a) or by flow cytometry analysis for cell surface PD-L1.
sgRNA oligonucleotides: Sequences:
human Pd-l1 guide 1: GGTTCCCAAGGACCTATATG
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sgRNA oligonucleotides: Sequences:
human Pd-l1 guide 2: ACAGAGGGCCCGGCTGTTGA
human Rab27a guide 1: CCAAAGCTAAAAACTTGATG
human RAB27a guide 2: CAACAGTGGGCATTGATTTC
Human nSMase2 guide 1: GAGAAACGCAAAGGGCAGCG
Human nSMase2 guide 2: CGGTCCACCAGCCAGTAGCA
mouse Pd-l1 guide 1: GTTTACTATCACGGCTCCAA
mouse Pd-l1 guide 2: GGGGAGAGCCTCGCTGCCAA
mouse RAB27a guide 1: CCAAGGCCAAGAACTTGATG
mouse RAB27a guide 2: CACAGTGGGCATTGATTTCA
mouse nSMase2 guide 1: CGTTAATGGCCGACTGGCTC
mouse nSMase2 guide 2: AATGCCAAGTGGTTAAAGGA
Electron Microscopy—Exosome sucrose float fractions where prepared as described 
above and resuspended in PBS. Sample aliquots of 4 μL were pipetted onto 200 mesh 
formvar/carbon grids (EMS) which had been glow-discharged for 15 s. Samples were 
incubated on grids for 30 s and subsequently negatively stained with a 2% uranyl acetate 
solution. Data were acquired using a Philips CM200F electron microscope operating at 200 
keV equipped with an UltraScan 1000 CCD Camera (Gatan).
Nanoparticle Tracking Analysis—200K cells were seeded per well (6 wells plate, 
Corning, cat. 3516) in KSR media 24 hours before collection for PC3 DU145 SK-MEL-28. 
100K cells cells were seeded in KSR media 24 hours before collection for TRAMP-C2 and 
MC38. Media was pre-processed at 300 g for 10 minutes at room temperature, followed by 
2k g for 20 min at 4°C then 12k g for 40 minutes at 4°C. The processed media was analyzed 
on a NanoSight LM10.
Antibodies
Immunoblotting: Anti-human PD-L1 (E1L3N) (Cell Signaling technology, cat. 13684T), 
anti-mouse PD-L1 (mouse) (EPR20529) (Abcam, cat. AB213480), anti-human CD63 
(MEM-259) (ABCAM, cat. ab8219) GAPDH (FL-335) (Santa Cruz Biotechnology, cat. 
Sc25778), anti-human HRS (c-7) (Santa Cruz biotechnology, cat. SC-271455). Anti-human/
mouse RAB27A (D7Z9Q) (Cell Signaling Technology, cat. 69295S). Anti-human nSMase2 
(Santa Cruz Biotechnology, sc-166637)
Flow Cytometry: Anti-human CD274 (B7-H1) PE (MIH1) (eBioscience, cat. 125983-42), 
PE mouse IgG2b, k Isotype control (MG2b-57) (Biolegend, cat. 401209).
Immunofluorescence: Primary antibody: Anti-human PD-L1 (E1L3N) (cell signaling 
technology, cat. 13684T). Secondary Antibody: Anti-Rabbit Alexa Fluor 680 (Thermo 
Fisher Scientific, cat. A10043).
Western Blot Analysis—Samples were lysed in RIPA buffer (Thermo Scientific, cat. 
89900) with the addition of PhosSTOP (Sigma-Aldrich, 4906837001) and Complete Mini 
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proteasome inhibitors (Sigma-Aldrich, 05892791001). Western Blot was performed as 
described in the commercially available antibody protocols listed above. Western blot band 
intensity quantification was calculated using ImageJ.
Raji - Jurkat T cell stimulation assay—Raji B cells were pre-loaded by adding 30 
ng/ml SEE superantigen in the media and incubating for 45 min at 37°C. Raji B cells were 
then washed and irradiated 10,000 rads prior to coculture. In a 96 wells plate (flat bottom) 
17,000 Raji B cells were co-cultured with 70,000 Jurkat T cells. Vesicles were derived from 
32 pates (15 cm plate, each plate seeded with 5 millions of cells 48 hours prior media 
collection) and added to the co-cultured cells as illustrated in Figure 2H. Human IL-2 was 
quantified from the media by ELISA (R&D Systems,#DY202–05).
Immunofluorescence—Cells were cultured in 8-wells chambered coverglass (Nunc, cat. 
154534). Cells were fixed with 4% PFA in PBS (Fisher Scientific cat. NC9245948) and 
incubated for 10 minutes at room temperature. After, PBS (Sigma, cat. RNBG9030) + 0.2% 
of Triton-X (VWR, cat. VW8609–0) was added and the samples permeabilized in solution 
for 10 minutes at room temperature. Following permeabilization, samples were blocked in 
5% Goat Serum (Invitrogen, cat. 16210064) PBS for 30 minutes at room temperature, and 
incubated at 4C overnight with primary antibodies (1:20). The following day, secondary was 
added (1:500) to the samples after washing, then incubated at room temperature for 3 hours. 
Prior imaging, sample were mounted with VECTASHIELD Antifade Mounting Medium 
with DAPI (Fisher Scientific, cat. NC9524612). Samples were imaged using NIKON 
spinning disk confocal.
Polysome Fractionation and RNA isolation—PC3 and SK-Mel-28 cells were pre-
treated for 10 min with 100 μg/ml cycloheximide (Sigma) added in media for 10 min. Cells 
were washed with cold PBS (Sigma, cat. RNBG9030) with 100 μg/ml cycloheximide 
(Sigma, cat. C4859) and scraped. Cell pellets were lysed in 10mM Tris-HCl pH8 (Fisher 
Scientific, cat. BP1531), 140mM NaCl (VWR, cat. JT4058–7), 1.5mM MgCl2 (Thermo 
Fisher Scientific, cat. R0971), 0.25% NP-40 (Fisher Scientific, cat. PI85124), 0.1% Triton 
X-100 (VWR, cat. VW8609–0), 50mM DTT (Thermo Fisher Scientific, cat. R0861), 150 
μg/ml cyclohexamide, (Sigma, cat. C4859) 640U/ml RNasin (Life Technology, cat. 
AM2696). After 30 min on ice, supernatant was separated by centrifugation at 9300 g and 
the supernatant transferred to a 10%–50% sucrose gradient. Samples were centrifuged at 35k 
g for 3 hours at 4C. After centrifugation the sample was fractionated (BIOCOMP). Samples 
were DNase treated.
Reverse transcriptase-quantitative PCR—DU145, PC3, LNCaP and SK-Mel-28 
RNA was isolated with QIAZOL Reagent (QIAGEN, cat. 79306), and purified with Pure 
Link RNA mini kit (QIAGEN, 12183018A). RNA was eluted in H2O and reverse-
transcribed to cDNA following the kit protocol (Thermo Scientific, cat. FERK1672). Eluted 
(1:50) cDNA samples were run on 7900HT fast real-time PCR system using SYBR green 
(Roche, cat. 04913914001).
Pd-l1 qPCR forward primer: GGCATTTGCTGAACGCAT, Pd-l1 qPCR reverse primer: 
CAATTAGTGCAGCCAGGT (Casey et al., 2016).
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Rpl7 qPCR forward primer: GAACCATGGAGGGTGTAGAAGAG, Rpl7 qPCR reverse 
primer: GGCAAACTTCTTTCTCAGGCG.
Cell Fractionation—Five million PC3 cells were collected (trypsin) from a 15 cm plate. 
Cells were washed with 10 mL of media. Cells were then re-suspended in 5 mL of lysosome 
lysis buffer (1M Sucrose, 1 M Tricine pH 7.2, 0.5M EDTA pH 8, and water). Cells were 
spun at 900 g for 5 min at 4C. Cells were suspended up to 1.5 mL or working buffer (lysis 
buffer plus Protease Inhibitor, phosTOP). 1.4 ml of cell suspension were passed through cell 
homogenizer (Isobiotec) using a 12um ball bearing (#7,9880) for 15 times. Cell lysate were 
spun at 700 g for 10 minutes and the supernatant collected. Pellet was re-suspended with 
working buffer equivalent to the previous collected supernatant and re-spun at 700 g. Pool of 
supernatants was spun at 3,000 g for 15 min. Pellet was collected for western blot. The 
supernatant from 3kg was further spun at 25,000 g for 25 minutes in a TLA 100.3 tube 
(Beckman Coulter). The pellet was processed into a sucrose gradient and the supernatant 
was further spun at 100,000 g for 30 minutes. The pellet and the supernatant were collected 
for western. The pellet from the 25k g spin was spun in a sucrose gradient made of layers of 
1.25M, 1.10M, and 0.25M sucrose in a TLS-55 tube (Beckman Coulter) at 120000 g for 1.5 
hours. The interphase between 1.25M and 1.1M (Sucrose Light) and the pellet were 
collected. Both collections were run in the Western Blot.
Biotin-Streptavidin Assay—Cell were biotin-labeled (Sigma Aldrich, cat. B4639). Cells 
were washed and incubated for 24 hours in fresh media. Exosomes were then isolated from 
cell-conditioned media, lysed, and then biotin-labeled proteins were pulled down by 
streptavidin-conjugated beads (Thermo Scientific, cat. 65001).
Tumor cells injections—Mice were injected (S.C.) with a million TRAMP-c2 WT or 
TRAMP-c2 Pd-l1 null or TRAMP-c2 Rab27a null or TRAMP-c2 nSMase2 null cells. Mice 
were injected (S.C. with a million MC38 WT or MC38 Pd-l1 null or MC38 Rab27a null 
cells. Mice were considered “end stage” when the tumor reached 2 cm in at least one 
dimension. Tumor growth was monitored three times a week by measuring tumor length and 
width. Tumor volume was calculated according to the following equation: length × width × 
0.5 × width (Faustino-Rocha et al., 2013).
Mice Treatments—Where indicated, mice were treated with 200 mg antibody I.P. at days 
7, 10, and 13 post tumor injection: anti–PD-L1 (10F.9G2) (BioXCell, cat. BE0101), isotype 
control (10F.9G2) (BioXCell, cat. LTF-2). Were indicated, mice were treated with 2.5 mg/kg 
GW4869 (Sigma-Aldrich, cat. D1692) from day 0 to day 14 once a day. Where indicated 
mice were treated with exosomes injected IV in the tail vein. 15 million cells were seeded in 
five 15 cm dishes (Corning CLS430599), and cultured for 48 hours. Vesicles were isolated 
as a 100k g pellet as described above. MC38 vesicles were resuspended in 1 mL PBS and 
TRAMP-C2 vesicles in 600 μl. Each mouse was injected with 100 μl of PBS containing 
vesicles.
Immune-Profiling—Mice were implanted subcutaneously (S.C.) with a million of 
TRAMP-C2 wt, Pd-l1 null, or Rab27a null cells. Alternately, mice were injected with 
TRAMP-C2 Rab27a and treated with exosomes derived from TRAMP-C2 WT or TRAMP-
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C2 Pd-l1 cells. Mice were euthanized and spleens and lymph nodes collected 14 days after 
tumor cell injection.
Spleens were surgically removed with sterilized surgical equipment, weighed, and crushed 
with the blunt end of a 10 mL syringe on Petri dishes containing 5 mL of PBS. The spleen 
mixtures were separately filtered through a 70 mM filter into a 50 mL conical tube, 
centrifuged at 1500 rpm for 5 minutes at 4°C. After wash, cell pellets were resuspended in 
5mL of red blood cell lysis solution (Santa Cruz Biotechnology; Cat sc-296258) on ice for 5 
minutes and stopped with the addition of 30mL of PBS. After wash, cells were reconstituted 
for counting by Vi-Cell (Beckman Coulter, U.S.A.). Draining lymph nodes (DLNs) were 
extracted with sterilized surgical equipment and crushed between the frosted surfaces of 
super-frosted microscope slides into wells containing PBS. Cell mixtures were then filtered 
through a 70 mm filter into 15 mL conical tubes. Cells were then washed and counted.
Single cell suspensions (1 million cells) were first incubated with Fc Block (Tombo 
Biosciences, cat. 70–0161) for 10 minutes, then co-incubated with antibodies for 20 minutes 
at 4°C followed by washing with staining buffer (PBS + 1% FBS). FoxP3 and intracellular 
staining were performed using an eBioscience intracellular kit (Cat#00-5523-00) according 
to the manufacturer’s protocol. Flow cytometry was performed on Fortessa X20 Dual, and 
data analyzed by FlowJo software (TreeStar). Details on flow cytometry antibodies used in 
this study can be found in Table S1.
Haematoxylin and eosin staining—Mice were sacrificed and the subcutaneous tumors 
were dissected. Tumors were fixed in 10% formalin (Fisher, cat. SF98–4) at room 
temperature overnight and consequentially dehydrated in 70% ethanol. Samples were 
mounted in paraffin blocks and sectioned at 5 μm of thickness. Haematoxylin and eosin 
staining was performed in Lecia Autostainer XL. Briefly, slides were baked at 60°C for 15 
minutes, then treated with Xylene Substitute (Citrisolv) (Fisher chemical cat. x3p-1gal) then 
rehydrated and stained with Hematoxylin, followed with washes with running water. An 
incubation with Acid Alcohol (Sigma, cat. A3429) was performed, followed with washes 
with running water. The samples were then stained with eosin (Thermo Scientific) then 
dehydrated with ethanol followed by Xylene Substitute (Citrisolv). Samples were mounted 
with Permount (Fisher Scientific, cat. SP15–500). Slides were submitted for pathologic 
evaluation. Pathologist was blinded to sample origin (i.e., experimental versus control)
QUANTIFICATION AND STATISTICAL ANALYSIS
Differences between groups were calculated using Student t test. Logrank test was 
performed for survival analysis. 2-way ANOVA was performed for tumor growth analysis. 
Further statistical methods are detailed in the figure legends. Data was processed with 
GraphPad Prism, Version 7 (GraphPad Software). In all cases a P value of 0.05 and below 
was considered significant: p < 0.05 (*), p < 0.01(**) and p < 0.001 (***). Details regarding 
number of replicates and the definition of center/error bars can be found in legends.
DATA AVAILABILITY
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Highlights
• Genetic blockade of exosomal PD-L1 extends survival by promoting anti-
tumor immunity
• Exosomal PD-L1 suppresses T cell activity in the draining lymph node
• Exosome-deficient tumor cells induce systemic anti-tumor immunity and 
memory
• Exosomal PD-L1 appears to be resistant to anti-PD-L1 antibody blockade
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Figure 1. Differential Secretion of PD-L1 in PC3 versus SK-MEL-28 Cells
(A) qRT-PCR of Pd-l1 mRNA levels in one melanoma cell line (SK-MEL-28) and three 
prostate cancer cell lines (LNCAP, PC3, and DU145). n = 3.
(B) Western analysis of cellular levels of PD-L1 in the same cells as (A). Top: 
Representative western blot. Bottom: Quantification of three independent western blots.
(C) Top left: Schematic for crude isolation of secreted vesicles by sequential centrifugation 
of media through increasing centrifugal forces and finally pelleted at 100k g. Bottom left: 
Representative western blot of PD-L1 in cells versus secreted vesicles of either PC3 or SK-
MEL-28 cells. Right: Quantification. n = 6.
(D) Nanoparticle tracking of size and quantity of secreted vesicles produced by PC3 and SK-
MEL-28 cells. Left: Density plot for size. Right: Total vesicle number based on integration 
under the curve. n = 9.
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(E) Schematic of steps involved in exosome purification including sequential centrifugations 
of supernatant at increasing gravitation force and then 100k g pellet run on sucrose gradient. 
Location of exosomes is followed by a western blot for CD63.
(F) Western blot for PD-L1 and exosome markers CD63 and HRS in different sucrose 
gradient fractions. n = 3.
(A and B) Error bars represent SD. (C and D) Error bars represent SEM. *p < 0.05; **p < 
0.01; ***p < 0.001 (Student’s t test).
See also Figures S1 and S2.
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Figure 2. PD-L1 Is Secreted in the Form of Rab27a- and nSMase2-Dependent Exosomes
(A) Nanoparticle tracking of size and quantity of GFP+ vesicles from WT and Rab27a null 
PC3 cells expressing CD63-GFP. Left: Density trace. Right: Integration under curve for total 
particles. n = 3.
(B–D) Electron microscopy images of WT (B), Rab27a null (C), and nSMase2 (D) null PC3 
exosomes, respectively, purified on sucrose gradient.
(E) Representative western for PD-L1 and CD63 in WT PC3, Rab27a null, and nSMase2 
null PC3 cells.
(F) Quantification of PD-L1 in WT PC3, Rab27a null, and nSMase2 null PC3 cells. n = 6.
(G) Schematic of in vitro functional assay of exosomal PDL1.
(H) Quantification of IL-2 released by Jurkat cells following Raji presentation of super-
antigen. Jurkat (PD1), Jurkat T cells overexpressing PD1; Raji (Parental), Raji B cells 
expressing low levels of PD-L1; Raji (PD-L1), Raji B cells overexpressing PD-L1; PC3 
Poggio et al. Page 26
Cell. Author manuscript; available in PMC 2019 May 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
vesicles, 100k g pellet from conditioned media of WT PC3 cells; PC3 Pd-l1−/− Vesc, 100k g 
pellet from conditioned media of Pd-l1 null PC3 cells. n = 4.
(A, F, and H) Error bars represent SD. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t test).
See also Figures S3 and S4.
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Figure 3. Exosomal PD-L1 Suppresses Tumor Progression in Syngeneic Prostate Cancer Model
(A) Western blot for PD-L1 in WT, Rab27a null, and Pd-l1 null TRAMP-C2 100k g 
extracellular fraction.
(B) Cell counts over time for Pd-l1 null versus WT TRAMP-C2 cells. n = 3. Error bars 
represent SD.
(C) Cell counts over time for Rab27a null versus WT TRAMP-C2 cells. n = 3. Error bars 
represent SD.
(D) Tumor growth volume over time following subcutaneous injection of 1 × 106 WT, 
Rab27a null, or Pd-l1 null TRAMP-C2 cells into immuno-competent B6 mice. n = 5 for 
each genotype. Error bars represent SEM. Tramp WT versus TRAMP-C2 Rab27a null, p < 
0.001. Tramp WT versus TRAMP-C2 Pd-l1 null, p < 0.0001. Tramp WT versus TRAMP-C2 
nSMase2 null, p < 0.001 (twoway ANOVA test).
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(E) Mouse survival curve following injection of cells like in (D). n = 10 for each genotype. 
Tramp WT versus TRAMP-C2 Rab27a null, p < 0.001. Tramp WT versus TRAMP-C2 Pd-l1 
null, p < 0.001. Tramp WT versus TRAMP-C2 nSMase2 null, p < 0.001 (log rank test).
(F) Mouse survival curve following NOD-SCID IL2rg−/− (NSG) mice injected with 1 × 106 
WT, Rab27a null, and Pd-l1 null TRAMP-C2 cells. n = 10 for Pd-l1 null and WT genotypes, 
n = 8 for Rab27a null genotype, n = 5 for nSMase2 null genotype.
See also Figure S5.
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Figure 4. Immunophenotypes of Draining Lymph Node T Cells Predicts Immune Memory and 
Tumor Suppression
(A) Schematic of experimental design for (B)–(M).
(B) Spleen weight in grams 14 days post-injection with 1 × 106 WT, Pd-l1 null, and Rab27a 
null TRAMP-C2 cells.
(C–E) Flow cytometric quantification of the percentage of CD8+ (C), CD4+ (D), and 
regulatory T cells (T-reg) (E), respectively, among CD45+, CD3+ cells in the draining lymph 
node (DLN) (n = 5 mice/genotype) 14 days post-tumor cell injection (1 × 106 WT, Pd-l1 
null, and Rab27a null TRAMP-C2 cells).
(F and G) Quantification of PD-1+ cells among CD8 (F) and CD4 (G) T cells (n = 5 mice/
genotype).
(H and I) Quantification of Tim3+ in CD8 (H) and CD4 (I) cells (n = 5 mice/genotype).
(J–M) Quantification of granzyme B (GzmB) (J and K) or Ki67 (L and M) CD8 (J and L) 
and CD4 (K and M) T cells (n = 5 mice/genotype). *p < 0.5; **p < 0.01 (Student’s t test).
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(N) Schematic of experimental design for (O).
(O) Tumor growth volume over time following secondary subcutaneous injection of 1 × 106 
WT TRAMP-C2 cells into immunocompetent B6 mice previously sham treated or injected 
with Pd-l1, Rab27a, or nSMase2 null TRAMP-C2 cells. n = 5 for each condition. Tramp WT 
versus TRAMP-C2 WT pre-injected with TRAMP-C2 Rab27a null, p < 0.001. Tramp WT 
versus TRAMP-C2 WT pre-injected with TRAMP-C2 Pd-l1 null, p < 0.001. Tramp WT 
versus TRAMP-C2 WT pre-injected with TRAMP-C2 nSMase2 null, p < 0.001 (two-way 
ANOVA test). Error bars represent SEM.
See also Figure S6.
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Figure 5. Exosomal PD-L1 Suppresses Tumor Progression in Syngeneic Colorectal Cancer Model
(A) Western for PD-L1 in WT and Rab27a null MC38 100k g extracellular fraction.
(B) Flow cytometry for surface PD-L1 on MC38 cells.
(C) Cell counts over time for Rab27a null versus WT MC38 cells. n = 3. Error bars represent 
SD.
(D) Cell counts over time for Pd-l1 null versus WT MC38 cells. n = 3. Error bars represent 
SD.
(E) Tumor growth over time following subcutaneous injection of 1 × 106 WT, Rab27a null, 
or Pd-l1 null MC38 cells into immunocompetent B6 mice. n = 5 for each genotype. Error 
bars represent SEM. MC38 WT versus MC38 Rab27a null, p < 0.05. MC38 WT versus 
MC38 Pd-l1 null, p < 0.05. MC38 WT versus MC38 Pd-l1 null; Rab27a null, p < 0.05 (two-
way ANOVA test).
(F) Mouse survival curve following injection of cells like in (D). n = 10 for each genotype. 
MC38 WT versus MC38 Rab27a null, p < 0.001. MC38 WT versus MC38 Pd-l1 null, p < 
0.001. MC38 WT versus MC38 Pd-l1 null; Rab27a null, p < 0.001 (log rank test).
(G) Survival curve for mice injected with WT, Rab27a null, or Pd-l1 null MC38 cells 
followed by treatment with either anti-PD-L1 or isotype control antibody. n = 5 for each 
condition. MC38 WT isotype versus MC38 WT anti-PD-L1, p < 0.01. MC38 Rab27a 
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isotype versus MC38 Rab27a anti-PD-L1, p < 0.05. MC38 Pd-l1 isotype versus MC38 
Rab27a anti-PD-L1, ns. (log rank test).
See also Figure S7.
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Figure 6. Cross-Communication between WT and Mutant TRAMP-C2 Cells at Distant Sites
(A) Schematic of the experiment: briefly, immuno-competent B6 mice were co-injected with 
1 × 106 mutant TRAMP-C2 cells in one flank and with 1 × 106 WT TRAMP-C2 cells in the 
other flank.
(B) Tumor growth of WT TRAMP-C2 cells in mice singly injected or co-injected with either 
Pd-l1 null or Rab27a null cells. n = 5 for each condition. Tramp WT versus TRAMP-C2 WT 
co-injected with TRAMP-C2 Rab27a null, p < 0.001. Tramp WT versus TRAMP-C2 WT 
co-injected with TRAMP-C2 Pd-l1 null, p < 0.001. Tramp WT versus TRAMP-C2 WT co-
injected with TRAMP-C2 nSMase2 null, p < 0.01 (two-way ANOVA test). Error bars 
represent SEM.
(C) Tumor growth of Pd-l1 null or Rab27a null TRAMP-C2 cells in mice singly injected or 
co-injected with WT TRAMP-C2 cells. n = 5 for each condition. Error bars represent SEM.
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(D) Mouse survival curve mice singly injected with WT TRAMP-C2 cells or doubly injected 
with WT and Pd-l1 null or Rab27a null cells. n = 5 for each genotype.
(E) Histological analysis of lymphocyte infiltration of tumors under the noted conditions. 
Each symbol represents an individual mouse. Representative images for each state (severe, 
moderate, mild, and none) can be found in Figure S7E.
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Figure 7. Exogenously Introduced Exosomal PD-L1 Rescues Immune Suppression and Tumor 
Growth of Rab27a Null Tumors
(A) Schematic of experimental design (B)–(K); briefly, mice were transplanted with 1 × 106 
Rab27a null TRAMP-C2 cells, followed by 3 times per week tail-vein injections of 
exosomes that were collected from either WT or Pd-l1 null TRAMP-C2 cells grown in vitro. 
Immune analysis was performed at 14 days.
(B) Spleen weight in grams.
(C–E) Flow cytometric quantification of the percentage of CD45+ CD3+ cells that are CD8 
(C), CD4 (D), and regulatory T cells (T-reg) (E), respectively, in the draining lymph node 
(DLN).
(F and G) Quantification of the percentage PD-1+ cells among the CD8 (F) and CD4 (G) T 
cell populations.
(H and I) Quantification of the percentage of Tim3+ cells among the CD8 (H) and CD4 (I) T 
cell populations.
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(J and K) Quantification of the percentage of granzyme B (GzmB+) cells among the CD8 (J) 
and CD4 (K) T cell populations.
(B–K) Each dot represents an individual mouse. Error bars represent mean and SD. *p < 
0.05; **p < 0.01; ***p < 0.001 (Student’s t test).
(L) Tumor growth over time following subcutaneous injection of 1 × 106 MC38 Rab27a null 
cells followed by tail vein exosomes derived from MC38 WT and MC38 Pd-l1 null cells 
grown in vitro. MC38 Rab27a null treated with WT versus Pd-l1 null exosomes, p < 0.01 
(two-way ANOVA test).(M) Survival curve following injection of cells as in (L). MC38 
Rab27a null tumors treated with WT versus Pd-l1 null exosomes, p < 0.01 (log rank test).
(L and M) Error bars represent SEM.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Immunoblotting: anti-human PD-L1 (E1L3N) Cell Signaling technology cat. 13684; RRID:AB_2687655
Immunoblotting: anti-mouse PD-L1 (mouse) 
(EPR20529)
Abcam cat. AB213480
Immunoblotting: anti-human CD63 (MEM-259) Abcam cat. AB8219; RRID:AB_306364
Immunoblotting: anti-human/mouse GAPDH (FL-335) Santa Cruz Biotechnology cat. SC-25778; RRID:AB_10167668
Immunoblotting: anti-human HRS (c-7) Santa Cruz biotechnology cat. SC-271455; RRID:AB_10648901
Immunoblotting: Anti-human/mouse RAB27A (D7Z9Q) Cell Signaling Technology cat. 69295
Immunoblotting: Anti-human nSMase2 (G-6) Santa Cruz Biotechnology cat. SC-166637; RRID:AB_2270817
Flow Cytometry: Anti-human CD274 (B7-H1) PE 
(MIH1)
eBioscience cat. 255983–42; RRID:AB_1907368
Flow Cytometry: PE mouse IgG2b, k Isotype control 
(MG2b-57)
Biolegend cat. 401209
immunofluorescence: Primary antibody: Anti-human 
PD-L1 (E1L3N)
Cell Signaling Technology cat. 13684; RRID:AB_2687655
immunofluorescence: Secondary Antibody: Anti-Rabbit 
Alexa Fluor 680
Thermo Fisher Scientific cat. A10043; RRID:AB_2534018
Antibodies for Immunophenotyping see Table S1 This paper N/A
anti-PD-L1 (10F.9G2) BioXCell cat. BE0101; RRID:AB_10949073
isotype control 971 (10F.9G2) BioXCell cat. LTF-2; RRID:AB_1107780
ELISA: IL-2 R&D System cat. DY202–05
Chemicals, Peptides, and Recombinant Proteins
BafA1 Cell Signaling cat. 54645S
MG132 SIGMA cat. M7449
PNGase F Sigma-Aldrich cat. P7367
Endo H NEB cat. P0702S
Human IFN-γ PeproT ech cat. 300–02
Mouse IFN-γ Abcam cat. AB9922
GW4869 Sigma-Aldrich cat. D1692
RIPA buffer Thermo Scientific cat. 89900
PhosSTOP Sigma-Aldrich cat. 4906837001
Complete Mini proteasome inhibitors Sigma-Aldrich cat. 05892791001
Triton-X VWR cat. VW8609–0
VECTASHIELD Antifade Mounting Medium with 
DAPI
Fisher Scientific cat. NC9524612
cycloheximide Sigma cat. C4859
Tris-HCl pH8 Fisher Scientific cat. BP1531
NaCl VWR cat. JT4058–7
MgCl2 Thermo Fisher Scientific cat. R0971
NP-40 Fisher Scientific cat.PI85124
DTT Thermo Fisher Scientific cat. R0861
RNasin Life Technology cat. AM2696
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REAGENT or RESOURCE SOURCE IDENTIFIER
SYBR green Roche cat. 04913914001
Biotin Sigma Aldrich cat. B4639
streptavidin-conjugated beads Thermo Scientific cat. 65001
Formalin Fisher cat. SF98–4
Xylene Substitute (Citrisolv) Fisher chemical cat. x3p-1gal
Acid Alcohol Sigma cat. A3429
Permount Fisher Scientific cat. SP15–500
Critical Commercial Assays
FUGENE HD Promega cat. E2311
QIAZOL Reagent QIAGEN cat. 79306
Pure Link RNA mini kit QIAGEN cat. 12183018A
Thermo Scientific Maxima First Strand cDNA Synthesis 
Kit for RT-qPCR
Thermo Scientific cat. FERK1672
Red blood cell lysis solution Santa Cruz Biotechnology cat. SC-296258
Zombie UV Fixable Viability Kit Biolegend cat. 423107
Intracellular kit eBioscience cat. 00-5523-100100
Deposited Data
Uncropped Western Blots Mendeley dataset https://doi.org/10.17632/4d8h97z4c8.1
Experimental Models: Cell Lines
PC3 ATCC CRL-1435; RRID:CVCL_0035
DU145 ATCC HTB-81; RRID:CVCL_0105
LnCap ATCC CRL-1740; RRID:CVCL_1379
SK-MEL-28 Robert Judson Lab (UCSF) RRID:CVCL_0526
293 T ATCC CRL-3216; RRID:CVCL_0063
RAJI B CELLS Ron Vale Lab (UCSF) RRID:CVCL_0511
JURKAT T-CELLS Overexpressing PD-1 Ron Vale Lab (UCSF) https://doi.org/10.1126/science.aaf1292
RAJI B CELLS Overexpressing PD-L1 Ron Vale Lab (UCSF) https://doi.org/10.1126/science.aaf1292
TRAMP-C2 ATCC CRL-2731; RRID:CVCL_3615
MC38 Jeffrey Schlom lab (NCI) RRID:CVCL_B288
Experimental Models: Organisms/Strains
C57BL/6J The Jackson Laboratory RRID:IMSR_JAX:000664
NCG (NOD-Prkdcem26Cd52Il2rgem26Cd22/NjuCrl) Charles River Laboratories RRID:IMSR_CRL:572
Oligonucleotides
Sequences for sgRNAs, see table in STAR Methods This paper N/A
Pd-l1 qPCR forward primer: 
GGCATTTGCTGAACGCAT
Casey et al., 2016 https://doi.org/10.1126/science.aac9935
Pd-l1 qPCR reverse primer: 
CAATTAGTGCAGCCAGGT
Casey et al., 2016 https://doi.org/10.1126/science.aac9935
Rpl7 qPCR forward primer: 
GAACCATGGAGGGTGTAGAAGAG
This paper N/A
Rpl7 qPCR reverse primer: GGCAAACTTC 
lllCTCAGGCG
This paper N/A
Recombinant DNA
pSpCas9(BB)-2A-GFP ADDGENE PX458
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REAGENT or RESOURCE SOURCE IDENTIFIER
pMH243-CD63-GFP Hebrok Lab (UCSF) N/A
Software
FlowJo 10.5.2 https://www.flowjo.com/
Prism 7.0b https://www.graphpad.com/scientific-software/prism/
ImageJ 1.49V https://imagej.nih.gov/ij
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